Abstract
Adenosine is an important molecule that exerts control on the immune system, by signaling through receptors lying on the surface of immune cells. This nucleotide is produced, in part, by the action of the ectoenzymes CD39 and CD73. Interestingly, these proteins are expressed on the cell surface of regulatory T-cells (Tregs) and mesenchymal stromal cells (MSCs)—two cell populations that have emerged as potential therapeutic tools in the field of cell therapy. In fact, the production of adenosine constitutes a mechanism used by both cell types to control the immune response. Recently, great scientific progress was obtained regarding the role of adenosine in the inflammatory environment. In this context, the present review focuses on the advances related to the impact of adenosine production over the immune modulatory activity of Tregs and MSCs, and how this nucleotide controls the biological functions of these cells. Finally, we mention the main challenges and hurdles to bring such molecule to clinical settings.
Similar content being viewed by others
References
Chen J-F, Eltzschig HK, Fredholm BB (2013) Adenosine receptors as drug targets—what are the challenges? Nat Rev Drug Discov 12:265–86. doi:10.1038/nrd3955
Allard B, Turcotte M, Stagg J (2012) CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol 2012:485156. doi:10.1155/2012/485156
Kaczmarek E, Koziak K, Sévigny J et al (1996) Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 271:33116–33122. doi:10.1074/jbc.271.51.33116
Resta R, Yamashita Y, Thompson LF (1998) Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 161:95–109. doi:10.1111/j.1600-065X.1998.tb01574.x
Alam M, Costales M, Cavanaugh C, Williams K (2015) Extracellular adenosine generation in the regulation of pro-inflammatory responses and pathogen colonization. Biomolecules 5:775–792. doi:10.3390/biom5020775
Haskó G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759–770. doi:10.1038/nrd2638
Yegutkin GG (2008) Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta Mol Cell Res 1783:673–694. doi:10.1016/j.bbamcr.2008.01.024
Corriden R, Insel PA (2012) New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors. Purinergic Signal 8:587–598. doi:10.1007/s11302-012-9311-x
Bono MR, Fernández D, Flores-Santibáñez F et al (2015) CD73 and CD39 ectonucleotidases in T cell differentiation: beyond immunosuppression. FEBS Lett 589:3454–3460. doi:10.1016/j.febslet.2015.07.027
Cunha R a (2005) Neuroprotection by adenosine in the brain: from A(1) receptor activation to A (2A) receptor blockade. Purinergic Signal 1:111–34. doi:10.1007/s11302-005-0649-1
Ngamsri K-C, Wagner R, Vollmer I et al (2010) Adenosine receptor A1 regulates polymorphonuclear cell trafficking and microvascular permeability in lipopolysaccharide-induced lung injury. J Immunol 185:4374–84. doi:10.4049/jimmunol.1000433
Liao Y, Takashima S, Asano Y et al (2003) Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res 93:759–766. doi:10.1161/01.RES.0000094744.88220.62
Kim J, Kim M, Song JH, Lee HT (2008) Endogenous A1 adenosine receptors protect against hepatic ischemia reperfusion injury in mice. Liver Transpl 14:845–54. doi:10.1002/lt.21432
Lee HT, Gallos G, Nasr SH, Emala CW (2004) A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol 15:102–111
Chen L, Fredholm BB, Jondal M (2008) Adenosine, through the A1 receptor, inhibits vesicular MHC class I cross-presentation by resting DC. Mol Immunol 45:2247–2254. doi:10.1016/j.molimm.2007.11.016
Yip L, Taylor C, Whiting CC, Fathman CG (2013) Diminished adenosine A1 receptor expression in pancreatic α-cells may contribute to the pathology of type 1 diabetes. Diabetes 62:4208–19. doi:10.2337/db13-0614
Rosin DL, Robeva A, Woodard RL et al (1998) Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol 401:163–186
Kilpatrick EL, Narayan P, Mentzer RM, Lasley RD (2002) Cardiac myocyte adenosine A2a receptor activation fails to alter cAMP or contractility: role of receptor localization. Am J Physiol Heart Circ Physiol 282:H1035–40. doi:10.1152/ajpheart.00808.2001
Olanrewaju H a, Mustafa SJ (2000) Adenosine A(2A) and A(2B) receptors mediated nitric oxide production in coronary artery endothelial cells. Gen Pharmacol 35:171–177. doi:10.1016/S0306-3623(01)00107-0
Fagerlund MJ, Kåhlin J, Ebberyd A et al (2010) The human carotid body: expression of oxygen sensing and signaling genes of relevance for anesthesia. Anesthesiology 113:1270–9. doi:10.1097/ALN.0b013e3181fac061
Huang S, Apasov S, Koshiba M, Sitkovsky M (1997) Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90:1600–1610
Milne GR, Palmer TM (2011) Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. ScientificWorldJournal 11:320–39. doi:10.1100/tsw.2011.22
Yang Z, Day YJ, Toufektsian MC et al (2005) Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 111:2190–2197. doi:10.1161/01.CIR.0000163586.62253.A5
Shryock JC, Snowdy S, Baraldi PG et al (1998) A2A-adenosine receptor reserve for coronary vasodilation. Circulation 98:711–718. doi:10.1161/01.CIR.98.7.711
Satoh S, Matsumura H, Hayaishi O (1998) Involvement of adenosine A(2A) receptor in sleep promotion. Eur J Pharmacol 351:155–162. doi:10.1016/S0014-2999(98)00302-1
Panther E, Idzko M, Herouy Y et al (2001) Expression and function of adenosine receptors in human dendritic cells. FASEB J 15:1963–70. doi:10.1096/fj.01-0169com
Salmon JE, Cronstein BN (1990) Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory. J Immunol 145:2235–40
Cronstein BN, Levin RI, Philips M et al (1992) Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol 148:2201–2206
Haskó G, Kuhel DG, Chen JF et al (2000) Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 14:2065–2074. doi:10.1096/fj.99-0508com
Raskovalova T, Lokshin A, Huang X et al (2007) Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res 67:5949–5956. doi:10.1158/0008-5472.CAN-06-4249
Mandapathil M, Hilldorfer B, Szczepanski MJ et al (2010) Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T Cells. J Biol Chem 285:7176–7186. doi:10.1074/jbc.M109.047423
Cekic C, Sag D, Day Y-J, Linden J (2013) Extracellular adenosine regulates naive T cell development and peripheral maintenance. J Exp Med 210:2693–706. doi:10.1084/jem.20130249
Eltzschig HK (2009) Adenosine: an old drug newly discovered. Anesthesiology 111:904–15. doi:10.1097/ALN.0b013e3181b060f2
Mirabet M, Herrera C, Cordero OJ et al (1999) Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation. J Cell Sci 112(Pt 4):491–502
Wakai A, Wang JH, Winter DC et al (2001) Adenosine inhibits neutrophil vascular endothelial growth factor release and transendothelial migration via A2B receptor activation. Shock 15:297–301
Marquardt DL, Walker LL, Heinemann S (1994) Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. J Immunol 152:4508–4515
Addi AB, Lefort A, Hua X et al (2008) Modulation of murine dendritic cell function by adenine nucleotides and adenosine: Involvement of the A2B receptor. Eur J Immunol 38:1610–1620. doi:10.1002/eji.200737781
Feoktistov I, Goldstein AE, Ryzhov S et al (2002) Differential expression of adenosine receptors in human endothelial cells: Role of A2B receptors in angiogenic factor regulation. Circ Res 90:531–538. doi:10.1161/01.RES.0000012203.21416.14
Dubey RK, Gillespie DG, Mi Z, Jackson EK (1997) Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: role of A2B receptors. Circulation 96:2656–2666. doi:10.1161/01.CIR.96.8.2656
Strohmeier GR, Reppert SM, Lencer WI, Madara JL (1995) The A2b adenosine receptor mediates cAMP responses to adenosine receptor agonists in human intestinal epithelia. J Biol Chem 270:2387–2394
Ansari HR, Nadeem A, Talukder M a H et al (2007) Evidence for the involvement of nitric oxide in A2B receptor-mediated vasorelaxation of mouse aorta. Am J Physiol Heart Circ Physiol 292:H719–25. doi:10.1152/ajpheart.00593.2006
Yang D, Koupenova M, Mccrann DJ et al (2008) The A2b adenosine receptor protects against vascular injury. Proc Natl Acad Sci 105:792–796. doi:10.1073/pnas.0705563105
Haskó G, Csóka B, Németh ZH et al (2009) A2B adenosine receptors in immunity and inflammation. Trends Immunol 30:263–270. doi:10.1016/j.it.2009.04.001
Figler RA, Wang G, Srinivasan S et al (2011) Links between Insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. Diabetes 60:669–679. doi:10.2337/db10-1070
Eckle T, Grenz A, Laucher S, Eltzschig HK (2008) A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin Invest 118:3301–3315. doi:10.1172/JCI34203
Zhou Y, Schneider DJ, Morschl E et al (2011) Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury. J Immunol 186:1097–106. doi:10.4049/jimmunol.1002907
Karmouty-Quintana H, Xia Y, Blackburn MR (2013) Adenosine signaling during acute and chronic disease states. J Mol Med (Berl) 91:173–81. doi:10.1007/s00109-013-0997-1
Fishman P, Bar-Yehuda S, Liang BT, Jacobson K a (2012) Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today 17:359–366. doi:10.1016/j.drudis.2011.10.007
Borea PA, Varani K, Vincenzi F et al (2015) The A3 adenosine receptor: history and perspectives. Pharmacol Rev 67:74–102. doi:10.1124/pr.113.008540
Hussain A, Gharanei AM, Nagra AS, Maddock HL (2014) Caspase inhibition via A3 adenosine receptors: a new cardioprotective mechanism against myocardial infarction. Cardiovasc Drugs Ther 28:19–32. doi:10.1007/s10557-013-6500-y
Baharav E, Bar-Yehuda S, Madi L et al (2005) Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 32:469–76
Fishman P, Bar-Yehuda S, Madi L et al (2006) The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther 8:R33. doi:10.1186/ar1887
Shevach EM, Thornton AM (2014) tTregs, pTregs, and iTregs: similarities and differences. Immunol Rev 259:88–102. doi:10.1111/imr.12160
Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562. doi:10.1146/annurev.immunol.21.120601.141122
Horwitz D a, Zheng SG, Gray JD (2008) Natural and TGF-beta-induced Foxp3+CD4+ CD25+ regulatory T cells are not mirror images of each other. Trends Immunol 29:429–435. doi:10.1016/j.it.2008.06.005
Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA (2001) A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 166:7282–7289
Zheng SG, Wang J, Wang P et al (2007) IL-2 is essential for TGF-β to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 178:2018–2027. doi:10.4049/jimmunol.178.4.2018
Lu L, Zhou X, Wang J et al (2010) Characterization of protective human CD4+CD25+ FOXP3+ regulatory T cells generated with IL-2, TGF-β and retinoic acid. PLoS One 5:1–12. doi:10.1371/journal.pone.0015150
Wang J, Huizinga TWJ, Toes REM (2009) De novo generation and enhanced suppression of human CD4+CD25+ regulatory T cells by retinoic acid. J Immunol 183:4119–26. doi:10.4049/jimmunol.0901065
Haddad R, Saldanha-Araujo F (2014) Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: what do we know so far? Biomed Res Int 2014:216806. doi:10.1155/2014/216806
Melief SM, Schrama E, Brugman MH et al (2013) Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 31:1980–91. doi:10.1002/stem.1432
Cahill EF, Tobin LM, Carty F et al (2015) Jagged-1 is required for the expansion of CD4(+) CD25(+) FoxP3(+) regulatory T cells and tolerogenic dendritic cells by murine mesenchymal stromal cells. Stem Cell Res Ther 6:19. doi:10.1186/s13287-015-0021-5
Battaglia M, Stabilini A, Migliavacca B et al (2006) Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 177:8338–47. doi:10.4049/jimmunol.177.12.8338
Scottà C, Esposito M, Fazekasova H et al (2013) Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+CD25+FOXP3+ T regulatory cell subpopulations. Haematologica 98:1291–1299. doi:10.3324/haematol.2012.074088
Long S, Buckner JH (2008) Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells. J Autoimmun 30:293–302
Singh Y, Garden OA, Lang F, Cobb BS (2015) MicroRNA-15b/16 enhances the induction of regulatory T cells by regulating the expression of Rictor and mTOR. J Immunol 195:5667–5677. doi:10.4049/jimmunol.1401875
Warth SC, Hoefig KP, Hiekel A et al (2015) Induced miR-99a expression represses Mtor cooperatively with miR-150 to promote regulatory T-cell differentiation. EMBO J 34:1195–213, doi:10.15252/embj.201489589
Mandapathil M, Lang S, Gorelik E, Whiteside TL (2009) Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods 346:55–63. doi:10.1016/j.jim.2009.05.004
Schuler PJ, Harasymczuk M, Schilling B et al (2011) Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods 369:59–68. doi:10.1016/j.jim.2011.04.004
Gautron A-S, Dominguez-Villar M, de Marcken M, Hafler D a (2014) Enhanced suppressor function of TIM-3(+) FoxP3(+) regulatory T cells. Eur J Immunol 44(9):2703–11. doi:10.1002/eji.201344392
Uraushihara K, Kanai T, Ko K et al (2003) Regulation of murine inflammatory bowel disease by CD25+ and CD25–CD4+ glucocorticoid-induced TNF receptor family-related gene+ regulatory T cells. J Immunol 171:708–716. doi:10.4049/jimmunol.171.2.708
Mahic M, Henjum K, Yaqub S et al (2008) Generation of highly suppressive adaptive CD8+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation. Eur J Immunol 38:640–646. doi:10.1002/eji.200737529
Chang CC, Ciubotariu R, Manavalan JS et al (2002) Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3:237–243. doi:10.1038/ni760
Fischer K, Voelkl S, Heymann J et al (2005) Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(−)CD8- double-negative regulatory T cells. Blood 105:2828–2835. doi:10.1182/blood-2004-07-2583
Shi Z, Okuno Y, Rifa’i M et al (2009) Human CD8+CXCR3+ T cells have the same function as murine CD8+CD122+ Treg. Eur J Immunol 39:2106–2119. doi:10.1002/eji.200939314
Brisslert M, Bokarewa M, Larsson P et al (2006) Phenotypic and functional characterization of human CD25+ B cells. Immunology 117:548–557. doi:10.1111/j.1365-2567.2006.02331.x
Nagaraj S, Gabrilovich DI (2007) Myeloid-derived suppressor cells. Adv Exp Med Biol 601:213–223
Hoechst B, Gamrekelashvili J, Manns MP et al (2011) Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 117:6532–6541. doi:10.1182/blood-2010-11-317321
Flores-Borja F, Bosma A, Ng D et al (2013) CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 5:173ra23. doi:10.1126/scitranslmed.3005407
Sakaguchi S, Wing K, Onishi Y et al (2009) Regulatory T cells: how do they suppress immune responses? Int Immunol 21:1105–1111. doi:10.1093/intimm/dxp095
Zheng Y, Josefowicz SZ, Kas A et al (2007) Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445:936–940. doi:10.1038/nature05563
Thornton AM, Shevach EM (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287–296. doi:10.1084/jem.188.2.287
Boussiotis VA, Tsai EY, Yunis EJ et al (2000) IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 105:1317–1325. doi:10.1172/JCI9918
Dieckmann D, Plottner H, Berchtold S et al (2001) Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 193:1303–10. doi:10.1084/jem.193.11.1303
Hsu P, Santner-Nanan B, Hu M et al (2015) IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1. J Immunol 195:3665–3674. doi:10.4049/jimmunol.1402898
Horwitz DA, Zheng SG, Gray JD (2003) The role of the combination of IL-2 and TGF-β or IL-10 in the generation and function of CD4+ CD25+ and CD8+regulatory T cell subsets. J Leukoc Biol 74:471–478. doi:10.1189/jlb.0503228
Dieckmann D, Bruett CH, Ploettner H et al (2002) Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med 196:247–253. doi:10.1084/jem.20020642
Collison LW, Workman CJ, Kuo TT et al (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:566–569. doi:10.1038/nature06306
Shuai X, Wei-Min L, Tong Y et al (2015) Expression of IL-37 contributes to the immunosuppressive property of human CD4+CD25+ regulatory T cells. Sci Rep 5:14478. doi:10.1038/srep14478
Agarwal A, Fanelli G, Letizia M et al (2014) Regulatory T cell-derived exosomes: possible therapeutic and diagnostic tools in transplantation. Front Immunol 5:555. doi:10.3389/fimmu.2014.00555
Levings MK, Sangregorio R, Sartirana C et al (2002) Human CD25+CD4+ T suppressor cell clones produce transforming growth factor, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 196:1335–1346. doi:10.1084/jem.20021139
Nakamura K, Kitani A, Strober W (2001) Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 194:629–44. doi:10.1084/jem.194.5.629
Annunziato F, Cosmi L, Liotta F et al (2002) Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J Exp Med 196:379–387. doi:10.1084/jem.20020110
Piccirillo CA, Letterio JJ, Thornton AM et al (2002) CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med 196:237–246
Kullberg MC, Hay V, Cheever AW et al (2005) TGF-beta1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation. Eur J Immunol 35:2886–95. doi:10.1002/eji.200526106
Grossman WJ, Verbsky JW, Barchet W et al (2004) Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21:589–601. doi:10.1016/j.immuni.2004.09.002
Deaglio S, Dwyer KM, Gao W et al (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204:1257–65. doi:10.1084/jem.20062512
Dwyer KM, Hanidziar D, Putheti P et al (2010) Expression of CD39 by human peripheral blood CD4+CD25 + T cells denotes a regulatory memory phenotype. Am J Transplant 10:2410–2420. doi:10.1111/j.1600-6143.2010.03291.x
Borsellino G, Kleinewietfeld M, Di Mitri D et al (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood 110:1225–1232. doi:10.1182/blood-2006-12-064527
Kobie JJ, Shah PR, Yang L et al (2006) T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5’-adenosine monophosphate to adenosine. J Immunol 177:6780–6786. doi:10.4049/jimmunol.177.10.6780
Horenstein AL, Chillemi A, Zaccarello G et al (2013) A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology 2, e26246. doi:10.4161/onci.26246
Haskó G, Cronstein BN (2004) Adenosine: an endogenous regulator of innate immunity. Trends Immunol 25:33–39. doi:10.1016/j.it.2003.11.003
Kaku H, Cheng KF, Al-Abed Y, Rothstein TL (2014) A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production. J Immunol 193:5904–13. doi:10.4049/jimmunol.1400336
Saze Z, Schuler PJ, Hong C-S et al (2013) Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood 122:9–18. doi:10.1182/blood-2013-02-482406
Morandi F, Horenstein AL, Chillemi A et al (2015) CD56brightCD16- NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation. J Immunol 195:965–72. doi:10.4049/jimmunol.1500591
Clayton A, Al-Taei S, Webber J et al (2011) Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 187:676–683. doi:10.4049/jimmunol.1003884
Schuler PJ, Saze Z, Hong CS et al (2014) Human CD4+CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol 177:531–543. doi:10.1111/cei.12354
Whiteside TL, Mandapathil M, Schuler P (2011) The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem 18:5217–5223. doi:10.2174/092986711798184334
Mandapathil M, Szczepanski MJ, Szajnik M et al (2010) Adenosine and prostaglandin e2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 285:27571–27580. doi:10.1074/jbc.M110.127100
Hoskin DW, Mader JS, Furlong SJ et al (2008) Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (review). Int J Oncol 32:527–535
Dwyer KM, Deaglio S, Gao W et al (2007) CD39 and control of cellular immune responses. Purinergic Signal 3:171–180. doi:10.1007/s11302-006-9050-y
Ring S, Pushkarevskaya A, Schild H et al (2015) Regulatory T cell-derived adenosine induces dendritic cell migration through the Epac-Rap1 pathway. J Immunol 194:3735–44. doi:10.4049/jimmunol.1401434
Narravula S, Lennon PF, Mueller BU, Colgan SP (2000) Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function. J Immunol 165:5262–5268. doi:10.4049/jimmunol.165.9.5262
Ohta A, Kini R, Ohta A et al (2012) The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol 3:190. doi:10.3389/fimmu.2012.00190
Ehrentraut H, Westrich JA, Eltzschig HK, Clambey ET (2012) Adora2b adenosine receptor engagement enhances regulatory T cell abundance during endotoxin-induced pulmonary inflammation. PLoS One 7(2):e32416. doi:10.1371/journal.pone.0032416
Friedenstein AJ et al (1974) Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17:331–340. doi:10.1097/00007890-197404000-00001
Caplan A (1991) Mesenchymal stem cells. J Orthop Res 9:641–50. doi:10.1002/jor.1100090504
Zuk P a, Zhu M, Mizuno H et al (2001) Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7:211–28. doi:10.1089/107632701300062859
Toma JG, Akhavan M, Fernandes KJ et al (2001) Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol 3:778–84. doi:10.1038/ncb0901-778
De Bari C, Dell’accio F, Tylzanowski P, Luyten FP (2001) Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 44:1928–1942. doi:10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P
Romanov YA, Svintsitskaya VA, Smirnov VN (2003) Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells 22:105–110. doi:10.1634/stemcells.21-1-111
Sabatini F, Petecchia L, Tavian M et al (2005) Human bronchial fibroblasts exhibit a mesenchymal stem cell phenotype and multilineage differentiating potentialities. Lab Investig 85:962–971. doi:10.1038/labinvest.3700300
da Silva ML, Caplan AI, Nardi NB et al (2008) In search of the in vivo identity of mesenchymal stem cells. Stem Cells 26:2287–99. doi:10.1634/stemcells.2007-1122
Covas DT, Panepucci R a, Fontes AM et al (2008) Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146 + perivascular cells and fibroblasts. Exp Hematol 36:642–654. doi:10.1016/j.exphem.2007.12.015
Steinert AF, Rackwitz L, Gilbert F et al (2012) Concise review: the clinical application of mesenchymal stem cells for musculoskeletal regeneration: current status and perspectives. Stem Cells Transl Med 1:237–47. doi:10.5966/sctm.2011-0036
Behfar A, Crespo-Diaz R, Terzic A, Gersh BJ (2014) Cell therapy for cardiac repair—lessons from clinical trials. Nat Rev Cardiol 11:232–46. doi:10.1038/nrcardio.2014.9
Rosado-De-Castro PH, Pimentel-Coelho PM, da Fonseca LMB et al (2013) The rise of cell therapy trials for stroke: review of published and registered studies. Stem Cells Dev 22:2095–111. doi:10.1089/scd.2013.0089
Domínguez-Bendala J, Lanzoni G, Inverardi L, Ricordi C (2012) Concise review: mesenchymal stem cells for diabetes. Stem Cells Transl Med 1:59–63. doi:10.5966/sctm.2011-0017
Sokal EM (2014) Treating inborn errors of liver metabolism with stem cells: current clinical development. J Inherit Metab Dis 37:535–539. doi:10.1007/s10545-014-9691-x
Munir H, Mcgettrick HM (2015) Mesenchymal stem cells therapy for autoimmune disease: risks and rewards. Stem Cells Dev 24:2091–2100. doi:10.1089/scd.2015.0008
Hahn JY, Cho HJ, Kang HJ et al (2008) Pre-treatment of mesenchymal atem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 51:933–943. doi:10.1016/j.jacc.2007.11.040
Khubutiya MS, Vagabov AV, Temnov AA, Sklifas AN (2014) Paracrine mechanisms of proliferative, anti-apoptotic and anti-inflammatory effects of mesenchymal stromal cells in models ofacute organ injury. Cytotherapy 16:579–585. doi:10.1016/j.jcyt.2013.07.017
Carvalho JL, Braga VBA, Melo MB et al (2013) Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction. J Cell Mol Med 17:617–625. doi:10.1111/jcmm.12036
Hu X, Yu SP, Fraser JL et al (2008) Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 135:799–808. doi:10.1016/j.jtcvs.2007.07.071
Di Nicola M, Carlo-Stella C, Magni M et al (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838–3843. doi:10.1182/blood.V99.10.3838
Bartholomew A, Sturgeon C, Siatskas M et al (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30:42–8. doi:10.1016/S0301-472X(01)00769-X
Le Blanc K, Rasmusson I, Sundberg B et al (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439–1441. doi:10.1016/S0140-6736(04)16104-7
Frassoni F, Labopin M, Bacigalupo A et al (2002) Expanded mesenchymal stem cells (MSC), co-infused with HLA identical hematopoietic stem cell transplants, reduce acute and chronic graft-versus-host disease: a matched pair analysis. Bone Marrow Transplant 29:s2, abstract
Martin P, Uberti J, Soiffer R et al (2010) Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Trasnplant 16:S169–S170
Cyranoski D (2012) Canada approves stem cell product. Nat Biotechnol 30:571
Vaes B, Van’t Hof W, Deans R, Pinxteren J (2012) Application of Multistem® allogeneic cells for immunomodulatory therapy: clinical progress and pre-clinical challenges in prophylaxis for graft versus host disease. Front Immunol 3:345. doi:10.3389/fimmu.2012.00345
Klyushnenkova E, Mosca JD, Zernetkina V et al (2005) T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 12:47–57. doi:10.1007/s11373-004-8183-7
Najar M, Raicevic G, Kazan HF et al (2012) Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming. Stem Cell Rev Rep 8:1188–1198. doi:10.1007/s12015-012-9408-1
Le Blanc K, Tammik L, Sundberg B et al (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57:11–20. doi:10.1046/j.1365-3083.2003.01176.x
Ghannam S, Pène J, Torcy-Moquet G et al (2010) Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 185:302–312. doi:10.4049/jimmunol.0902007
Luz-Crawford P, Kurte M, Bravo-Alegría J et al (2013) Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther 4:65. doi:10.1186/scrt216
Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815–1822. doi:10.1182/blood-2004-04-1559
Saldanha-Araujo F, Haddad R, Malmegrim De Farias KCR et al (2012) Mesenchymal stem cells promote the sustained expression of CD69 on activated T lymphocytes: Roles of canonical and non-canonical NF-kB signalling. J Cell Mol Med 16:1232–1244. doi:10.1111/j.1582-4934.2011.01391.x
Jiang X-X, Zhang Y, Liu B et al (2005) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105:4120–4126. doi:10.1182/blood-2004-02-0586.Supported
Maccario R, Podestà M, Moretta A et al (2005) Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4 + T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90:516–525
Nauta AJ, Kruisselbrink AB, Lurvink E et al (2006) Mesenchymal stem cells inhibit generation and function of both CD34+−derived and monocyte-derived dendritic cells. J Immunol 177:2080–2087
Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L (2009) MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113:6576–6583. doi:10.1182/blood-2009-02-203943
Zhang W, Ge W, Li C et al (2004) Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 13:263–71. doi:10.1089/154732804323099190
Krampera M, Cosmi L, Angeli R et al (2006) Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24:386–98. doi:10.1634/stemcells.2005-0008
Sotiropoulou P a, Perez S a, Gritzapis AD et al (2006) Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24:74–85. doi:10.1634/stemcells.2004-0359
Corcione A, Benvenuto F, Ferretti E et al (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107:367–372. doi:10.1182/blood-2005-07-2657
Tabera S, Pérez-Simón JA, Díez-Campelo M et al (2008) The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 93:1301–1309. doi:10.3324/haematol.12857
Comoli P, Ginevri F, Maccario R et al (2008) Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant 23:1196–1202. doi:10.1093/ndt/gfm740
Rosado MM, Bernardo ME, Scarsella M et al (2015) Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev 24:93–103. doi:10.1089/scd.2014.0155
Mu CY, Huang JA, Chen Y et al (2011) High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 28:682–688. doi:10.1007/s12032-010-9515-2
He J, Hu Y, Hu M, Li B (2015) Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep 5:13110. doi:10.1038/srep13110
Chang C-J, Yen M-L, Chen Y-C et al (2006) Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells 24:2466–2477. doi:10.1634/stemcells.2006-0071
Munn DH, Mellor AL (2013) Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 34:137–143. doi:10.1016/j.it.2012.10.001
English K, Ryan JM, Tobin L et al (2009) Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 156:149–60. doi:10.1111/j.1365-2249.2009.03874.x
Baratelli F, Lin Y, Zhu L et al (2005) Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 175:1483–1490. doi:10.4049/jimmunol.175.3.1483
Ryan JM, Barry F, Murphy JM, Mahon BP (2007) Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149:353–363. doi:10.1111/j.1365-2249.2007.03422.x
Maria Spaggiari G, Moretta L, Spaggiari GM, Moretta L (2013) Cellular and molecular interactions of mesenchymal stem cells in innate immunity. Immunol Cell Biol 91:27–31. doi:10.1038/icb.2012.62
Meisel R, Zibert A, Laryea M et al (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103:4619–4621. doi:10.1182/blood-2003-11-3909
Chinnadurai R, Copland IB, Patel SR, Galipeau J (2014) IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells. J Immunol 192:1491–501. doi:10.4049/jimmunol.1301828
Tomchuck SL, Zwezdaryk KJ, Coffelt SB et al (2008) Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26:99–107. doi:10.1634/stemcells.2007-0563
Meuwissen H, Pollara B, Pickering R (1975) Combined immunodeficiency disease associated with adenosine deaminase deficiency. Report on a workshop held in Albany, New York, October 1, 1973. J Pediatr 86:169–81
Kumar V (2013) Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal 9:145–165. doi:10.1007/s11302-012-9349-9
Blay J, White TD, Hoskin DW (1997) The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57:2602–2605
Ohta A, Sitkovsky M (2014) Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol 5:304. doi:10.3389/fimmu.2014.00304
Saldanha-Araujo F, Ferreira FIS, Palma PV et al (2011) Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes. Stem Cell Res 7:66–74. doi:10.1016/j.scr.2011.04.001
Kerkelä E, Laitinen A, Räbinä J et al (2016) Adenosinergic immunosuppression by human mesenchymal stromal cells requires co-operation with T cells. Stem Cells 34:781–90
Saldanha-Araujo F, Panepucci R a (2011) CD39 expression in mesenchymal stromal cells. J Immunother 34:568. doi:10.1097/CJI.0b013e3182298c8f
Sattler C, Steinsdoerfer M, Offers M et al (2010) Inhibition of T cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39/CD73 coexpression and adenosine generation. Cell Transplant 20:1221–1230. doi:10.3727/096368910X546553\rct0203sattler
Lee JJ, Jeong HJ, Kim MK et al (2013) CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function. Purinergic Signal 10(2):357–365. doi:10.1007/s11302-013-9385-0
Sundin M, D’Arcy P, Johansson CC et al (2011) Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity? J Immunother 34:336–42. doi:10.1097/CJI.0b013e318217007c
Chatterjee D, Tufa D, Baehre H et al (2014) Natural killer cells acquire CD73 expression upon exposure to mesenchymal stem cells. Blood 123:594–5
Cavaliere F, Donno C, D’Ambrosi N (2015) Purinergic signaling: a common pathway for neural and mesenchymal stem cell maintenance and differentiation. Front Cell Neurosci 9:211. doi:10.3389/fncel.2015.00211
Li P, Gao Y, Cao J et al (2015) CD39(+) regulatory T cells attenuate allergic airway inflammation. Clin Exp Allergy 45:1126–37. doi:10.1111/cea.12521
Yoshida O, Dou L, Kimura S et al (2015) CD39 deficiency in murine liver allografts promotes inflammatory injury and immune-mediated rejection. Transpl Immunol 32:76–83. doi:10.1016/j.trim.2015.01.003
Ehrentraut H, Clambey ET, Mcnamee EN et al (2013) CD73+ regulatory T cells contribute to adenosine-mediated resolution of acute lung injury. FASEB J 27:2207–19. doi:10.1096/fj.12-225201
Wang L, Fan J, Chen S et al (2013) Graft-versus-host disease is enhanced by selective CD73 blockade in mice. PLoS One 8(3), e58397. doi:10.1371/journal.pone.0058397
Chen X, Shao H, Zhi Y et al (2016) CD73 pathway contributes to the immunosuppressive ability of mesenchymal stem cells (MSCs) in intraocular autoimmune responses. Stem Cells Dev 25:337–46
Amarnath S, Foley JE, Farthing DE et al (2015) Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human th1 cells in vivo. Stem Cells 33:1200–1212. doi:10.1002/stem.1934
Burr SP, Dazzi F, Garden O a (2013) Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance? Immunol Cell Biol 91:12–8. doi:10.1038/icb.2012.60
Kinsey GR, Huang L, Jaworska K et al (2012) Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol 23:1528–37. doi:10.1681/ASN.2012010070
Kinsey GR, Sharma R, Okusa MD (2013) Regulatory T cells in AKI. J Am Soc Nephrol 24:1720–6. doi:10.1681/ASN.2013050502
Lim J-Y, Park M-J, Im K-I et al (2013) Combination cell therapy using mesenchymal stem cells and regulatory T cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of Th1/Th2 and Th17/Treg cells in a murine acute graft-versus-host disease model. Cell Transplant 23:703–714. doi:10.3727/096368913X664577
Zhou Y, Singh AK, Hoyt RF et al (2014) Regulatory T cells enhance mesenchymal stem cell survival and proliferation following autologous cotransplantation in ischemic myocardium. J Thorac Cardiovasc Surg 148:1131–7. doi:10.1016/j.jtcvs.2014.06.029
Cronstein B (2010) How does methotrexate suppress inflammation? Clin Exp Rheumatol 28(5 Suppl 61):S21–S23
Kreth S, Ledderose C, Luchting B et al (2010) Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock 34:10–6. doi:10.1097/SHK.0b013e3181cdc3e2
Cronstein BN, Montesinos MC, Weissmann G (1999) Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci U S A 96:6377–81. doi:10.1073/pnas.96.11.6377
Horrigan LA, Kelly JP, Connor TJ (2006) Immunomodulatory effects of caffeine: friend or foe? Pharmacol Ther 111:877–892. doi:10.1016/j.pharmthera.2006.02.002
Massie BM, O’Connor CM, Metra M et al (2010) Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 363:1419–1428. doi:10.1056/NEJMoa0912613
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This article does not contain any studies with human participants or animals performed by any of the authors.
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
de Oliveira Bravo, M., Carvalho, J.L. & Saldanha-Araujo, F. Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression. Purinergic Signalling 12, 595–609 (2016). https://doi.org/10.1007/s11302-016-9529-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11302-016-9529-0